DSIP

DSIP has a better provenance than most peptides sold to consumers and a weaker evidence base than its reputation suggests. It was isolated in the 1970s by Marcel Monnier and Guido Schoenenberger, who collected cerebral venous blood from rabbits during electrically induced sleep and found a factor that induced delta-wave sleep when transferred to recipient animals. The active principle turned out to be a nine-residue peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, which they named delta sleep-inducing peptide.

That origin story is the source of its appeal and also of a persistent problem. Fifty years later, no specific DSIP receptor has been identified, its endogenous concentrations and regulation are poorly characterised, and reviews continue to describe its physiological role as unsettled. A 2006 review in the Journal of Neurochemistry was titled, plainly, "a still unresolved riddle" [3]. An earlier comprehensive review in Neuroscience and Biobehavioral Reviews had already catalogued the inconsistencies two decades before that [4]. A molecule can be real, reproducibly synthesisable, and still lack a defined mechanism, and that is where DSIP sits.

The human evidence is genuine but narrow and old. In 1981 the Lancet published a report that synthetic DSIP improved sleep in insomniacs [1]. Studies through the 1980s in European Neurology and the International Journal of Clinical Pharmacology Research examined 24-hour sleep-wake behaviour and short-term administration in chronic insomnia. A double-blind study in Neuropsychobiology in 1992 remains the last controlled human work of note [2]. Taken together these trials involved small numbers of subjects, used intravenous administration at doses around 25 nanomoles per kilogram, and produced modest, somewhat inconsistent improvements in sleep latency and continuity rather than dramatic hypnotic effects. Importantly, DSIP did not behave like a sedative. Several investigators described improvements in sleep quality without the sedation profile of benzodiazepines, which is the more interesting claim and also the harder one to verify with these sample sizes.

Then the human literature simply stops. Nothing of comparable design has been published in more than thirty years. In pharmacology, a compound that produced a clear signal in the early 1980s and attracted no follow-up trials usually did so because the effect proved small, inconsistent or hard to reproduce, not because it was overlooked.

Animal work has continued. A 2021 study in Molecules reported that DSIP administration aided recovery of motor function in rats after focal stroke [5], and a 2018 Life Sciences paper found that a phosphorylated DSIP analogue restored spatial memory and CREB phosphorylation, apparently by improving sleep architecture rather than by acting directly on memory circuits. Other work has examined DSIP in relation to stress hormone responses, seizure thresholds and circadian regulation, including a 2009 review linking DSIP and glucocorticoid-induced leucine zipper as potential connectors between circadian and metabolic control. Those are interesting mechanistic threads. None of them is a human outcome.

The claims that DSIP reduces stress, normalises circadian rhythm and improves recovery are extensions of this animal and biochemical work rather than conclusions from human trials. They may well be true. They are not demonstrated.

Dosing in the community bears little relation to the clinical studies. Typical protocols call for 100 to 500 micrograms subcutaneously shortly before bed, with some sources going to 1 to 2 mg, whereas the historical trials used intravenous administration on a per-kilogram basis. Subcutaneous bioavailability, clearance and central penetration for this peptide have not been characterised in humans, so translating between routes is guesswork. DSIP is also chemically fragile in solution, which makes storage and reconstitution practices a real determinant of whether a user is administering anything active at all.

Safety, as far as the historical record goes, is reassuring: no serious adverse events were reported in the small controlled studies, and mild drowsiness is the effect most often described. That record cannot support conclusions about nightly use over months or years, which is how it is often used. The interaction most likely to matter has never been studied: additive sedation when combined with alcohol, benzodiazepines, z-drugs, sedating antihistamines or opioids. Anyone using DSIP should treat the first several doses as an unknown for next-day alertness and avoid driving until they know their own response.

Our position: DSIP earns tier 3 because controlled human data exists, which distinguishes it from most peptides in this category. It does not earn a recommendation. The trials are forty years old, small, and modest in effect; no receptor has been found; no modern study is registered; and the material available to buyers is unregulated research chemical. For someone with chronic insomnia, cognitive behavioural therapy for insomnia has vastly stronger evidence and no sourcing risk.